IRF3 promotes neuroinflammation in PD through the cGAS-STING pathway [76], yet it exhibits anti-inflammatory effects in AD and MS via the AKT/PI3K pathway [35,96] and suppresses inflammation in MS by modulating astrocyte miRNA [94]. This evidence concerns the gene IRF3 and myeloid sarcoma.